Figure 2From: Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function Incidence of AKI according to baseline eGFR categories in the RCC group. The incidence of all-cause AKI and everolimus-associated AKI increased progressively with decreasing eGFR (P = 0.029 and P = 0.004 for trend, respectively).Back to article page